文献速递慢性肾脏病血液净化与透析

Daprodustat与CKD患者心力衰竭住院风险

Daprodustat and Heart Failure in CKD.
PubMed 文献 · J Am Soc Nephrol · 2024-02-22

该研究基于ASCEND-D和ASCEND-ND两项试验,比较daprodustat与传统ESA对CKD贫血患者心力衰竭住院的影响。结果显示daprodustat组首次心衰住院数在非透析和透析患者中均数值上更多但未达统计学显著,事后分析中非透析患者总心衰住院率显著增加。

要点

  • 非透析CKD贫血患者使用daprodustat相比ESA,首次心衰住院风险数值升高但无统计学意义。
  • 事后分析中daprodustat显著增加非透析患者总心衰住院率,透析患者未见此差异。
  • 心衰病史、糖尿病和较高收缩压独立关联心衰住院风险。

核心结论

  • daprodustat组首次心衰住院事件数多于传统ESA组但未达统计学显著性。
  • 心衰住院差异在非透析患者和有心衰病史患者中最为明显。

研究设计与样本

  • 基于ASCEND-D(n=2964)和ASCEND-ND(n=3872)两项试验的事后分析,比较daprodustat与传统ESA。
  • 研究对象为CKD贫血患者,分别纳入需要透析和不需要透析的人群。

主要发现

  • 非透析患者首次心衰住院HR为1.22(95%CI 0.95-1.56,P=0.12)。
  • 透析患者首次心衰住院HR为1.10(95%CI 0.84-1.45,P=0.47)。
  • ASCEND-ND中心衰病史有vs无的HR为1.37(95%CI 0.89-2.11)vs 1.08(95%CI 0.79-1.46),P-interaction=0.36。
  • ASCEND-D中心衰病史有vs无的HR为1.52(95%CI 0.97-2.38)vs 0.93(95%CI 0.66-1.30),P-interaction=0.09。
  • 事后分析非透析患者总心衰住院率比1.46(95%CI 1.11-1.92,P=0.007),透析患者1.01(95%CI 0.74-1.39,P=0.93)。

关键数值与推荐

  • 心衰病史、糖尿病和较高收缩压在各试验中均独立关联心衰住院,与治疗分组无关。
  • daprodustat对首次心衰住院或死亡的复合结局风险无显著影响。

临床怎么用

  • 对非透析CKD贫血患者使用daprodustat时需关注心衰住院风险,尤其有心衰病史者。
  • 透析患者使用daprodustat的心衰住院风险信号相对较弱。

局限性

  • 心衰住院差异未达统计学显著性,事后分析结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Patients with CKD face meaningful risk of heart failure hospitalization. Daprodustat compared with darbepoetin was associated with a nonsignificantly greater number of heart failure hospitalizations in non-dialysis patients. BACKGROUND: Patients with CKD are at higher risk of heart failure. The hypoxia-inducible factor prolyl hydroxylase inhibitor daprodustat is an orally acting alternative to conventional injectable erythropoietin-stimulating agents (ESAs) for the treatment of anemia in patients with CKD. Whether daprodustat affects the risk of heart failure hospitalization is unknown. METHODS: The Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat–Dialysis (ASCEND-D; n=2964) and Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat–Non-Dialysis (ASCEND-ND; n=3872) trials compared daprodustat with conventional ESA in patients with anemia of CKD who did or did not require dialysis, respectively. We identified risk factors of heart failure hospitalization and assessed the effect of daprodustat compared with conventional ESA on heart failure hospitalizations. RESULTS: History of heart failure, diabetes, and higher systolic BP were independently associated with heart failure hospitalization in both trials, irrespective of treatment assignment. The number of first heart failure hospitalizations was greater in the daprodustat arm in patients not receiving dialysis (hazard ratio [HR], 1.22 [95% confidence interval (CI), 0.95 to 1.56], P = 0.12) and in patients receiving dialysis (HR, 1.10 [95% CI, 0.84 to 1.45], P = 0.47), although these differences were not statistically significant. HRs in patients with and without history of heart failure were 1.37 (95% CI, 0.89 to 2.11) versus 1.08 (95% CI, 0.79 to 1.46) (P-interaction=0.36) in the ASCEND-ND trial and 1.52 (95% CI, 0.97 to 2.38) versus 0.93 (95% CI, 0.66 to 1.30) (P-interaction=0.09) in the ASCEND-D trial, respectively. In post hoc analyses, daprodustat increased total (first and recurrent) heart failure hospitalizations in participants not receiving dialysis (rate ratio, 1.46 [95% CI, 1.11 to 1.92], P = 0.007) but not in participants receiving dialysis (rate ratio, 1.01 [95% CI, 0.74 to 1.39], P = 0.93). Daprodustat did not significantly affect the risk of a composite outcome of first heart failure hospitalization or death. CONCLUSIONS: A greater number of first heart failure hospitalization events occurred in patients treated with daprodustat compared with conventional ESA, but this difference did not reach statistical significance. Differences in the number of heart failure hospitalization events were most apparent in patients not receiving dialysis and in patients with history of heart failure. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2024_04_10_ASN0000000000000321.mp3

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Cunningham JW, Claggett BL, Lopes RD, et al. Daprodustat and Heart Failure in CKD. J Am Soc Nephrol. 2024. PMID: 38383961. doi:10.1681/ASN.0000000000000321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。